Wall Street brokerages expect that NuCana PLC (NASDAQ:NCNA) will report earnings per share of ($0.14) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for NuCana’s earnings, with estimates ranging from ($0.17) to ($0.11). The company is expected to report its next earnings report on Monday, January 1st.
Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover NuCana.
Separately, Zacks Investment Research lowered NuCana from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $21.00.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alps Advisors Inc. bought a new position in shares of NuCana in the 4th quarter worth $357,000. Sphera Funds Management LTD. bought a new position in shares of NuCana in the 3rd quarter worth $919,000. Citadel Advisors LLC bought a new position in shares of NuCana in the 3rd quarter worth $1,218,000. Alyeska Investment Group L.P. bought a new position in shares of NuCana in the 3rd quarter worth $2,296,000. Finally, Perceptive Advisors LLC bought a new position in shares of NuCana in the 3rd quarter worth $3,674,000. 30.70% of the stock is owned by hedge funds and other institutional investors.
NuCana Company Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.